Medindia

X

Rivaroxaban Plus Standard Antiplatelet Therapy Improves Survival After Myocardial Infarction

by Kathy Jones on  November 14, 2011 at 8:31 PM Drug News   - G J E 4
A new study published in the New England Journal of Medicine reveals that the oral anticoagulant rivaroxaban improves survival rates after a myocardial infarction when given in combination standard antiplatelet therapy
 Rivaroxaban Plus Standard Antiplatelet Therapy Improves Survival After Myocardial Infarction
Rivaroxaban Plus Standard Antiplatelet Therapy Improves Survival After Myocardial Infarction
Advertisement

More than 15,500 patients took part in the ATLAS-ACS 2-TIMI 51 trial and were given either a placebo or 2.5 mg or 5 mg of rivaroxaban for over a period of 13 months.

Advertisement
The number of cardiovascular deaths, MI, or strokes was lower in the group taking rivaroxaban at 8.9 percent compared to 10.7 percent in the placebo group.

Lead researcher Michael Gibson of Harvard, who presented the findings at the American Heart Association meeting, said that a number of deaths can be prevented if antiplatelet therapy is used to treat the patients. "One death would be prevented if 56 patients on antiplatelet therapies were treated for two years with rivaroxaban 2.5 mg twice daily", he said.


Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like